Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
NCT ID: NCT01177644
Last Updated: 2012-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)
NCT01186432
Safety and Preliminary Efficacy Study of V404 PDS in Uveitis
NCT02125266
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
NCT00109499
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT00473928
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
PDS 1.0
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PDS 1.0
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Retinal thickness due to edema of at least 300um in the study eye
* Best corrected visual acuity of 20/80 or worse in the study eye
* Best corrected visual acuity of 20/40 or better in the fellow eye
Exclusion Criteria
* Fibrosis \>75% of lesion area in the study eye
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forsight Vision4
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FSV4 FH-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.